Summary

This article presents results from the High Induction Therapy with Anti-Rheumatic Drugs study [HIT HARD], which compared treatment with adalimumab plus methotrexate with methotrexate monotherapy in disease-modifying antirheumatic drug (DMARD)-naïve patients with active early rheumatoid arthritis (RA). The central question of the study was whether or not early induction therapy with a subsequent step-down strategy leads to long-term clinical effect in patients with RA.